Abstract
Nuclear factor-κB (NF-κB) is a transcription factor that plays an important role in the immune system and cell death. Many viral proteins modulate NF-κB to escape host immune surveillance, promote cell survival, and enhance viral replication. In the present study, we show that NF-κB activity is downmodulated by viral interferon regulatory factor 3 (vIRF3), which is encoded by Kaposi's sarcoma-associated herpesvirus open-reading frame K10.5. vIRF3 repressed NF-κB-dependent transcription in a dose-dependent manner and inhibited the activation of NF-κB induced by tumor necrosis factor (TNF)-α. In vivo studies showed vIRF3 inhibited IκB kinase β (IKKβ) activity, but not IKKα activity, resulting in reduced IκB phosphorylation. Immunofluorescence assays showed that vIRF3 interfered with nuclear translocation of NF-κB. In addition, consistent with the inhibition of NF-κB activity, vIRF3 sensitized cells to TNF-α-induced apoptosis. While vIRF3 interacts with IKKβ in vitro and in 293T cells, we were unable to demonstrate vIRF3–IKKβ interaction in BCBL-1 cells. Our results indicate that vIRF3 can regulate the host immune system and apoptosis via inhibition of NF-κB activity.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 50 print issues and online access
$259.00 per year
only $5.18 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
Similar content being viewed by others
References
Baeuerle PA and Baltimore D . (1996). Cell, 87, 13–20.
Bakker TR, Reed D, Renno T and Jongeneel CV . (1999). Int. J. Cancer, 80, 320–323.
Barnes B, Lubyova B and Pitha PM . (2002). J. Interferon Cytokine Res., 22, 59–71.
Beg AA and Baltimore D . (1996). Science, 274, 782–784.
Brown HJ, Song MJ, Deng H, Wu T, Cheng G and Sun R . (2003). J. Virol., 77, 8532–8540.
Burysek L and Pitha PM . (2001). J. Virol., 75, 2345–2352.
Burysek L, Yeow WS, Lubyova B, Kellum M, Schafer SL, Huang YQ and Pitha PM . (1999a). J. Virol., 73, 7334–7342.
Burysek L, Yeow WS and Pitha PM . (1999b). J. Hum. Virol., 2, 19–32.
Cesarman E, Chang Y, Moore PS, Said JW and Knowles DM . (1995). N. Engl. J. Med., 332, 1186–1191.
Chang Y, Cesarman E, Pessin MS, Lee F, Culpepper J, Knowles DM and Moore PS . (1994). Science, 266, 1865–1869.
Chu WM, Ostertag D, Li ZW, Chang L, Chen Y, Hu Y, Williams B, Perrault J and Karin M . (1999). Immunity, 11, 721–731.
Ganem D . (1997). Cell, 91, 157–160.
Gao SJ, Boshoff C, Jayachandra S, Weiss RA, Chang Y and Moore PS . (1997). Oncogene, 15, 1979–1985.
Geleziunas R, Ferrell S, Lin X, Mu Y, Cunningham Jr ET, Grant M, Connelly MA, Hambor JE, Marcu KB and Greene WC . (1998). Mol. Cell. Biol., 18, 5157–5165.
Ghosh S and Karin M . (2002). Cell, 109 (Suppl), S81–S96.
Graham FL and van der Eb AJ . (1973). Virology, 52, 456–467.
Hiscott J, Kwon H and Genin P . (2001). J. Clin. Invest., 107, 143–151.
Hu J, Angell JE, Zhang J, Ma X, Seo T, Raha A, Hayashi J, Choe J and Kalvakolanu DV . (2002). J. Interferon Cytokine Res., 22, 1017–1026.
Hu Y, Baud V, Delhase M, Zhang P, Deerinck T, Ellisman M, Johnson R and Karin M . (1999). Science, 284, 316–320.
Hu Y, Baud V, Oga T, Kim KI, Yoshida K and Karin M . (2001). Nature, 410, 710–714.
Jiang Y, Woronicz JD, Liu W and Goeddel DV . (1999). Science, 283, 543–546.
Karin M and Ben-Neriah Y . (2000). Annu. Rev. Immunol., 18, 621–663.
Karin M and Lin A . (2002). Nat. Immunol., 3, 221–227.
Li M, Damania B, Alvarez X, Ogryzko V, Ozato K and Jung JU . (2000). Mol. Cell. Biol., 20, 8254–8263.
Li M, Lee H, Guo J, Neipel F, Fleckenstein B, Ozato K and Jung JU . (1998). J. Virol., 72, 5433–5440.
Li Q, Van Antwerp D, Mercurio F, Lee KF and Verma IM . (1999a). Science, 284, 321–325.
Li ZW, Chu W, Hu Y, Delhase M, Deerinck T, Ellisman M, Johnson R and Karin M . (1999b). J. Exp. Med., 189, 1839–1845.
Liu L, Eby MT, Rathore N, Shinha SK, Kumar A and Chaudhary PM . (2002). J. Biol. Chem., 277, 13745–13751.
Lubyova B, Kellum MJ, Frisancho AJ and Pitha PM . (2004). J. Biol. Chem., 279, 7643–7654.
Lubyova B and Pitha PM . (2000). J. Virol., 74, 8194–8201.
Moore PS and Chang Y . (1998). Trends Genet., 14, 144–150.
Nakamura H, Li M, Zarycki J and Jung JU . (2001). J. Virol., 75, 7572–7582.
Ouaaz F, Li M and Beg AA . (1999). J. Exp. Med., 189, 999–1004.
Rivas C, Thlick AE, Parravicini C, Moore PS and Chang Y . (2001). J. Virol., 75, 429–438.
Rothwarf DM and Karin M . (1999). Sci. STKE, 1999, RE1.
Rothwarf DM, Zandi E, Natoli G and Karin M . (1998). Nature, 395, 297–300.
Russo JJ, Bohenzky RA, Chien MC, Chen J, Yan M, Maddalena D, Parry JP, Peruzzi D, Edelman IS, Chang Y and Moore PS . (1996). Proc. Natl. Acad. Sci. USA, 93, 14862–14867.
Ryan KM, Ernst MK, Rice NR and Vousden KH . (2000). Nature, 404, 892–897.
Seo T, Lee D, Lee B, Chung JH and Choe J . (2000). Biochem. Biophys. Res. Commun., 270, 23–27.
Seo T, Lee D, Shim YS, Angell JE, Chidambaram NV, Kalvakolanu DV and Choe J . (2002). J. Virol., 76, 8797–8807.
Seo T, Park J, Lee D, Hwang SG and Choe J . (2001). J. Virol., 75, 6193–6198.
Shao R, Hu MC, Zhou BP, Lin SY, Chiao PJ, von Lindern RH, Spohn B and Hung MC . (1999). J. Biol. Chem., 274, 21495–21498.
Shao R, Karunagaran D, Zhou BP, Li K, Lo SS, Deng J, Chiao P and Hung MC . (1997). J. Biol. Chem., 272, 32739–32742.
Silverman N and Maniatis T . (2001). Genes Dev., 15, 2321–2342.
Simeonidis S, Stauber D, Chen G, Hendrickson WA and Thanos D . (1999). Proc. Natl. Acad. Sci. USA, 96, 49–54.
Soulier J, Grollet L, Oksenhendler E, Cacoub P, Cazals-Hatem D, Babinet P, d'Agay MF, Clauvel JP, Raphael M, Degos L and Sigaux F . (1995). Blood, 86, 1276–1280.
Spitkovsky D, Hehner SP, Hofmann TG, Moller A and Schmitz ML . (2002). J. Biol. Chem., 277, 25576–25582.
Thanos D and Maniatis T . (1995). Cell, 80, 529–532.
Van Antwerp DJ, Martin SJ, Kafri T, Green DR and Verma IM . (1996). Science, 274, 787–789.
Van Antwerp DJ, Martin SJ, Verma IM and Green DR . (1998). Trends Cell Biol., 8, 107–111.
Verma IM, Stevenson JK, Schwarz EM, Van Antwerp D and Miyamoto S . (1995). Genes Dev., 9, 2723–2735.
Wang CY, Mayo MW and Baldwin Jr AS . (1996). Science, 274, 784–787.
Whelan J, Ghersa P, Hooft van Huijsduijnen R, Gray J, Chandra G, Talabot F and DeLamarter JF . (1991). Nucleic Acids Res., 19, 2645–2653.
Zandi E, Rothwarf DM, Delhase M, Hayakawa M and Karin M . (1997). Cell, 91, 243–252.
Zimring JC, Goodbourn S and Offermann MK . (1998). J. Virol., 72, 701–707.
Acknowledgements
We thank Dr Yuan Chang for the vIRF3/LANA2 cDNA and monoclonal antibody against vIRF3/LANA2. This work was supported in part by the National Research Laboratory Program of the Korea Institute of Science and Technology Evaluation and Planning (KISTEP), by the Molecular Medicine Research Group Program of KISTEP through the Biomedical Research Center at Korea Advanced Institute of Science and Technology, and by the BK21 Program of the Ministry of Education, Republic of Korea.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Seo, T., Park, J., Lim, C. et al. Inhibition of nuclear factor κB activity by viral interferon regulatory factor 3 of Kaposi's sarcoma-associated herpesvirus. Oncogene 23, 6146–6155 (2004). https://doi.org/10.1038/sj.onc.1207807
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1038/sj.onc.1207807
Keywords
This article is cited by
-
Suppression of the SAP18/HDAC1 complex by targeting TRIM56 and Nanog is essential for oncogenic viral FLICE-inhibitory protein-induced acetylation of p65/RelA, NF-κB activation, and promotion of cell invasion and angiogenesis
Cell Death & Differentiation (2019)
-
The regulatory role of protein phosphorylation in human gammaherpesvirus associated cancers
Virologica Sinica (2017)
-
Kaposi’s sarcoma-associated herpesvirus lana2 protein interacts with the pocket proteins and inhibits their sumoylation
Oncogene (2014)
-
Dysregulation of KSHV replication by extracts from Carthamus tinctorius L.
Journal of Microbiology (2013)